Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

Mulshine, James

One or more keywords matched the following properties of Mulshine, James

Property	Value
overview	Other Appointments: Dean, Rush Graduate College (Acting) Vice President, Rush University Medical Center Overview: I have worked on translational research in lung cancer including prevention and biological-based biomarker development with multiple papers and patents related to this work over the last thirty five years. My primary interest has been in the management of early lung cancer. I have served on and chair a number of national and international research advisory boards co-chaired a panel to prioritize development of all relevant biomarkers used in the SPORE program in 2003. I started and led the Upper Aerodigestive Tumor Biology Faculty in the NCI Intramural Program. I have also been involved in technology development issues for many years and served on the NIH Director’s Tech Transfer Subcommittee for nine years while in Bethesda to provide advice on the approval of CRADAs for the intramural NIH programs. Have served as Associate Provost for Research at Rush University from 2005-2015, Acting Dean of the Rush Graduate College from 2012 to the present. Over much of that time, I had the lead responsibility for developing the appropriate infrastructural foundations for biomedical research and education at Rush and worked with the faculty to sustain a productive environment for research and faculty development. Initially my capacity as Associate Provost for Research, I have worked with Dr. Josh Jacobs and the leadership of the Rush research community as we have established a CTSA-like infrastructure funded by Rush institutional support. We worked with the leadership of the ITM over the last 5 years as an affiliate member and have harmonized our research infrastructure and key functions with the corresponding ITM processes. We are now well positioned to join in ITM 2.0 as a fully functional and complementary partner to University of Chicago in achieving the new vision and goals outlined in the current submission. This joint CTSA submission builds on the productive legacy of the PCORI collaboration in CAPriCORN which was led initially by David Meltzer of U of C and now by the Raj Shah of Rush. Other established areas of Rush/ University of Chicago are multiple but involvement in the community research consortium, C3 and the outcomes research consortium, Chicago Learn are two excellent examples of the ongoing success of the U of C/ Rush collaborations. Now over the last several years I have worked as the Acting Dean of the Graduate College and in that capacity have been involved in the planning of the training and mentoring activities proposed in the new CTSA application. Through considerable Rush institutional investment, we bring a totally reengineered Graduate college curriculum for translational research to the new ITM 2.0 effort. I have had a series of roles with ITM 1.0 and have worked to integrate the efforts of the ITM 2.0 with CAPriCORN in relevant setting in collaboration with Dr. Richard Kennedy by cross- walking the governance documents for the PCORI funded, CAPriCORN and the latest NCATS funding opportunity announcement to minimize administrative barriers to complementary activities. In my leadership role in the Graduate College at Rush, I have been responsible for a complete overhaul of the laboratory-based, PhD and Masters programs including implementing a new and sustainable funding model for Rush to greatly enhance its support of translational science PhD education. Supported by the medical bioinformatics faculty at Rush, we have introduced a new rapid learning/ big data course into the Masters of Sciences in Clinical Research curriculum to help our students in the transition to a population healthcare model. We co-developed with the other Chicago AMCs, a recent professional development forum with iBIO for graduate students and post-doctoral fellows in a series that we had previously hosted with the University of Illinois in Chicago. Going forward these events will be sponsored for all Chicago academic medical centers through an inclusive ITM/iBIO collaboration. I continue to maintain a research interest in the area of early lung cancer management especially as it related to quantitative imaging. My ORCID is 0000-0002-4648-9177. My Scopus is 24285376700. My NIH COMMONS name is Jmulshine. Education: BA 1974 College of the Holy Cross, Worcester (Biology) M.D. 1977 Loyola Stritch Medical School, Chicago (Medicine) Residency 1980 Cleveland Clinic Foundation, Cleveland (Internal Medicine) Fellowship 1983 National Cancer Institute, Bethesda (Medical Oncology)

Property

Value

overview

Other Appointments: Dean, Rush Graduate College (Acting) Vice President, Rush University Medical Center Overview: I have worked on translational research in lung cancer including prevention and biological-based biomarker development with multiple papers and patents related to this work over the last thirty five years. My primary interest has been in the management of early lung cancer. I have served on and chair a number of national and international research advisory boards co-chaired a panel to prioritize development of all relevant biomarkers used in the SPORE program in 2003. I started and led the Upper Aerodigestive Tumor Biology Faculty in the NCI Intramural Program. I have also been involved in technology development issues for many years and served on the NIH Director’s Tech Transfer Subcommittee for nine years while in Bethesda to provide advice on the approval of CRADAs for the intramural NIH programs. Have served as Associate Provost for Research at Rush University from 2005-2015, Acting Dean of the Rush Graduate College from 2012 to the present. Over much of that time, I had the lead responsibility for developing the appropriate infrastructural foundations for biomedical research and education at Rush and worked with the faculty to sustain a productive environment for research and faculty development. Initially my capacity as Associate Provost for Research, I have worked with Dr. Josh Jacobs and the leadership of the Rush research community as we have established a CTSA-like infrastructure funded by Rush institutional support. We worked with the leadership of the ITM over the last 5 years as an affiliate member and have harmonized our research infrastructure and key functions with the corresponding ITM processes. We are now well positioned to join in ITM 2.0 as a fully functional and complementary partner to University of Chicago in achieving the new vision and goals outlined in the current submission. This joint CTSA submission builds on the productive legacy of the PCORI collaboration in CAPriCORN which was led initially by David Meltzer of U of C and now by the Raj Shah of Rush. Other established areas of Rush/ University of Chicago are multiple but involvement in the community research consortium, C3 and the outcomes research consortium, Chicago Learn are two excellent examples of the ongoing success of the U of C/ Rush collaborations. Now over the last several years I have worked as the Acting Dean of the Graduate College and in that capacity have been involved in the planning of the training and mentoring activities proposed in the new CTSA application. Through considerable Rush institutional investment, we bring a totally reengineered Graduate college curriculum for translational research to the new ITM 2.0 effort. I have had a series of roles with ITM 1.0 and have worked to integrate the efforts of the ITM 2.0 with CAPriCORN in relevant setting in collaboration with Dr. Richard Kennedy by cross- walking the governance documents for the PCORI funded, CAPriCORN and the latest NCATS funding opportunity announcement to minimize administrative barriers to complementary activities. In my leadership role in the Graduate College at Rush, I have been responsible for a complete overhaul of the laboratory-based, PhD and Masters programs including implementing a new and sustainable funding model for Rush to greatly enhance its support of translational science PhD education. Supported by the medical bioinformatics faculty at Rush, we have introduced a new rapid learning/ big data course into the Masters of Sciences in Clinical Research curriculum to help our students in the transition to a population healthcare model. We co-developed with the other Chicago AMCs, a recent professional development forum with iBIO for graduate students and post-doctoral fellows in a series that we had previously hosted with the University of Illinois in Chicago. Going forward these events will be sponsored for all Chicago academic medical centers through an inclusive ITM/iBIO collaboration. I continue to maintain a research interest in the area of early lung cancer management especially as it related to quantitative imaging. My ORCID is 0000-0002-4648-9177. My Scopus is 24285376700. My NIH COMMONS name is Jmulshine. Education: BA 1974 College of the Holy Cross, Worcester (Biology) M.D. 1977 Loyola Stritch Medical School, Chicago (Medicine) Residency 1980 Cleveland Clinic Foundation, Cleveland (Internal Medicine) Fellowship 1983 National Cancer Institute, Bethesda (Medical Oncology)

One or more keywords matched the following items that are connected to Mulshine, James

Item Type	Name
Concept	Molecular Biology
Concept	Systems Biology
Academic Article	Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations.
Academic Article	Control of tumor cell biology through regulation of peptide hormone processing.
Academic Article	Biomedical imaging archive network.
Academic Article	One Screening for Ischemic Heart Disease, Lung Cancer, and Chronic Obstructive Pulmonary Disease: A Systems Biology Bridge for Tobacco and Radiation Exposure.

Search Criteria

Biology